Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer (Q38594474)

4 September 2017

title

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer (English)

1 reference

4 September 2017

Mazen Zaarour

1 reference

4 September 2017

Chanudi Weerasinghe

1 reference

4 September 2017

Bassel Nazha

1 reference

4 September 2017

Samer Hassan

1 reference

4 September 2017

Jean-Paul Atallah

1 reference

4 September 2017

publication date

28 September 2015

1 reference

Expert Review of Anticancer Therapy

4 September 2017

published in

1 reference

4 September 2017

1 reference

4 September 2017

1 reference

4 September 2017

page(s)

1327-1336

1 reference

Long-term trends in cancer mortality in the United States, 1930-1998.

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Non-Small Cell Lung Cancer, Version 6.2015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Novel therapeutic targets in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Afatinib for the treatment of metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Rociletinib in EGFR-mutated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1092385

10.1586/14737140.2015.1092385

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference